[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) – Form 4 insider filing dated 06/30/2025

Director Mette Kirstine Agger received a stock-option grant for 25,000 common shares on 06/26/2025 with an exercise price of $4.18 and an expiration date of 06/25/2035. The award vests 100% on the earlier of 06/26/2026 or the company’s next annual shareholder meeting, contingent on continued service. No non-derivative (share) transactions were reported, and the director’s beneficial ownership now includes 25,000 derivative securities. The filing represents routine equity compensation; it does not involve share purchases or sales and therefore has no immediate cash impact or dilution event.

Insights

Financial Analyst

TL;DR – Routine option grant; minimal financial impact for LXEO shareholders.

The Form 4 discloses a standard director compensation grant—25,000 options at $4.18, vesting within one year. Because there is no share issuance until exercise, near-term dilution is zero. Even if exercised, 25,000 shares are immaterial relative to a typical biotech float, suggesting negligible EPS or ownership effects. No buying or selling signal emerges; therefore, the event is viewed as operationally neutral.

Corporate Governance Expert

TL;DR – Grant aligns director incentives; corporate-governance neutral.

Granting options with a one-year vesting schedule is common practice to align directors’ interests with shareholders. The strike price mirrors prevailing market terms (exact share price not provided), indicating no preferential treatment. Filing timeliness and attorney-in-fact signature comply with Section 16 requirements. No red flags noted; impact on governance dynamics is neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agger Mette Kirstine

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.18	06/26/2025		A		25,000		(1)	06/25/2035	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LXEO disclose in the latest Form 4?

The company reported a grant of 25,000 stock options to director Mette Kirstine Agger on 06/26/2025 at an exercise price of $4.18.

When do the granted LXEO options vest?

They vest 100% on the earlier of 06/26/2026 or the company’s next annual stockholders meeting, subject to the director’s continuous service.

What is the expiration date of the new LXEO director options?

The options expire on 06/25/2035 if not exercised earlier.

Does the Form 4 show any LXEO share sales or purchases?

No. The filing only reports an option grant; no common-stock transactions occurred.

How many derivative securities does the director own after this transaction?

Following the grant, the director beneficially owns 25,000 derivative securities (stock options).